Interim data of effectiveness and safety of nivolumab plus ipilimumab combination therapy (NIVO plus IPI) in first line (1L) advanced/metastatic renal cell carcinoma (aRCC) from the German non-interventional study (NIS) NORA
ONCOLOGY RESEARCH AND TREATMENT（2022）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined